OTCMKTS:BNOEFBionomics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bionomics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.04 +0.01 (+17.14 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.04Now: $0.04▼$0.0550-Day Range$0.02MA: $0.03▼$0.0452-Week Range$0.01Now: $0.04▼$0.09Volume500 shsAverage Volume11,985 shsMarket Capitalization$22.33 millionP/E RatioN/ADividend YieldN/ABeta1.68 ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesSocial Media Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Bionomics. Previous Next 2.2 Community Rank Outperform VotesBionomics has received 45 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBionomics has received 59 “underperform” votes. (Add your “underperform” vote.)Community SentimentBionomics has received 56.73% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bionomics and other stocks. Vote “Outperform” if you believe BNOEF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BNOEF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBionomics does not currently pay a dividend.Dividend GrowthBionomics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bionomics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Noncommercial research organizations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BNOEF Previous Symbol CUSIPN/A CIKN/A WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares544,590,000Market Cap$22.33 million Next Earnings DateN/A OptionableNot Optionable OTC:BNOEF Rates by TradingView Receive BNOEF News and Ratings via Email Sign-up to receive the latest news and ratings for BNOEF and its competitors with MarketBeat's FREE daily newsletter. Bionomics (OTCMKTS:BNOEF) Frequently Asked Questions How has Bionomics' stock been impacted by COVID-19 (Coronavirus)? Bionomics' stock was trading at $0.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BNOEF shares have increased by 36.7% and is now trading at $0.0410. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Bionomics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bionomics. Has Bionomics been receiving favorable news coverage? News stories about BNOEF stock have been trending very positive this week, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bionomics earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutBionomics. Who are some of Bionomics' key competitors? Some companies that are related to Bionomics include Sundial Growers (SNDL), Neon Therapeutics (NTGN), Aquabounty Technologies (AQB), AquaBounty Technologies (AQB), Novoheart (NVH), Milestone Pharmaceuticals (MIST), Oncolytics Biotech (ONCY), Immunoprecise Antibodies (IPA), Clearside Biomedical (CLSD), Acasti Pharma (ACST), Omega Diagnostics Group (ORPH), Ampio Pharmaceuticals (AMPE), Otonomy (OTIC), Anpac Bio-Medical Science (ANPC) and Onconova Therapeutics (ONTX). View all competitors. Who are Bionomics' key executives? Bionomics' management team includes the following people: Dr. Errol B. De Souza, Exec. Chairman (Age 66)Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS, Legal Counsel & Company Sec.Prof. Paul Rolan, Consultant Medical Officer of Clinical Neuroscience What is Bionomics' stock symbol? Bionomics trades on the OTCMKTS under the ticker symbol "BNOEF." How do I buy shares of Bionomics? Shares of BNOEF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Bionomics' stock price today? One share of BNOEF stock can currently be purchased for approximately $0.04. How big of a company is Bionomics? Bionomics has a market capitalization of $22.33 million. This page was last updated on 6/4/2020 by MarketBeat.com Staff
